Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Mark Hallett MD
Mark Hallett MD Editor-in-Chief
Marinos Dalakas MD, FAAN
Marinos C. Dalakas MD, FAAN Advisory Board
Avindra Nath MD
Avindra Nath MD Associate Editor
See All Experts
Published in Neurology

Journal Scan / Research · August 27, 2022

Inhibition of the Angiotensin II Type 2 Receptor for Treating Glioblastoma

Proceedings of the National Academy of Sciences of the United States of America

 

 Save  Recommend
 Share

Additional Info

Proceedings of the National Academy of Sciences of the United States of America
Inhibition of the angiotensin II type 2 receptor AT2R is a novel therapeutic strategy for glioblastoma
Proc. Natl. Acad. Sci. U.S.A 2022 Aug 09;119(32)e2116289119, R Perryman, A Renziehausen, H Shaye, AD Kostagianni, AD Tsiailanis, T Thorne, MV Chatziathanasiadou, GB Sivolapenko, MA El Mubarak, GW Han, B Zarzycka, V Katritch, G Lebon, C Lo Nigro, L Lattanzio, SV Morse, JJ Choi, K O'Neill, Z Kanaki, A Klinakis, T Crook, V Cherezov, AG Tzakos, N Syed

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated